The Effect of Telmisartan and Irbesartan on Body Weight and its Contribution to Blood Pressure Control in Hypertensive Black Patients: A Retrospective Cohort Study
study has analyzed the extent of weight reducing ability among the “peroxisome
proliferator activated receptor-gamma” (PPAR-γ) activating ARBs – Telmisartan
and Irbesartan in black hypertensive of African origin. This retrospective
cohort study was designed to delineate the extent of weight reducing effect of
these PPAR-γ activating ARBs and how it correlates with BP reduction observed
with these ARBs in black hypertensive. A total of 26 case notes of patients (15
men, 11 women; mean age 58.9±1.8 years) with diagnosis of hypertension were
reviewed and the study attained a power of 96%. The patients whose case notes
were reviewed were naïve to ARBs before commencing either telmisartan or
irbesartan and did not have any metabolic disease like diabetes or thyroid
disease which could interfere with body weight reading. They all took either
telmisartan 80mg or irbesartan 150mg for at least a 6 month review period. Body
weight were significantly reduced more in the telmisartan (n = 13) treatment
group compared to the irbesartan(n = 13) treatment group [change from baseline; -1.51±0.46Kg (-1.68%), P=0.006 vs.
-0.96±0.15Kg (-1.05%), P<0.001].
Both treatment effectively controlled blood pressure (mean BP after 6 months
treatment: Telmisartan 126/83mmHg; Irbesartan 133/84mmHg). In the telmisartan
group there were no correlation between either change in SBP and change in body
weight (r = -0.220, P = 0.471) or change in DBP and change in body weight (r =
-0.050, P = 0.870), but a significant positive correlation was observed between
both change in SBP and change in body weight (r = 0.538, P = 0.058) and change
in DBP and change in body weight (r = 0.610, P = 0.027) in the irbesartan
treatment group. Both telmisartan and irbesartan reduced body weight in
hypertensive black patients and this reduction in body weight may contribute to
the power demonstrated by irbesartan to get patients to BP goal. Hence
hypertensive blacks could also benefit from the established end-organ
protection benefits of both telmisartan and irbesartan.
Hypertension; Telmisartan; Irbesartan; Body weight;
American Heart Association. Metabolic “footprint” may be new measure of obesity
risk in kids. 4TH annual conference on cardiovascular diseases, epidemiology
and prevention, 2004.
V.L., Whelton, P., Roccella, E.J., Brown, C., Cutler, J.A., Higgins, M., et al.
Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey.
1988-1991. Hypertension, 1995, 25(3),
R., Schupp, M., Foryst-Ludwig, Anna., et al. PPAR gamma-activating angiotensin
type-1 receptor blockers induce adiponectin. Hypertension, 2005, 46(1): 137-143.
las Heras, N., Martin-Fernandez B, Miana M, et al. The protective effect of
irbesartan in rats fed a high fat diet is associated with modification of
leptin-adiponectin imbalance. J Hypertens,
2009, 6(Suppl.): S37-41.
G., Cicero, A.F., D`Angelo, A., et al. Telmisartan and irbesartan therapy in
type 2 diabetic patients treated with rosiglitazone: effects in insulin
resistance, leptin and tumor necrosis factor-alpha. Hypertens Res., 2006, 11: 849-56.
M., Paschke, R., Stumvoll, M. Adiponectin, obesity and cardiovascular disease. Biochimie, 2004, 86: 779-784
J., Whelton, PK., Appel, L J., Charleston, J., Klag, MJ. Long-term effects of
weight loss and dietary sodium reduction on incidence of hypertension. Hypertension, 2000, 35:544-9.
Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril,
on cardiovascular events in high risk patients. N Engl J Med., 2000, 342: 145-53.
P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. Global burden of
hypertension: analysis of worldwide data. Lancet,
2005, 365: 217–23.
K.K., Quon, M.J., Han, S.H., et al. Vascular and metabolic effects of combined
therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension, 2005, 45: 1088-1093.
E.J., Hunsicker, L.G., Clarke, W.R., et al. for the Collaborative study group.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in
patients with nephropathy due to type 2 diabetes. N Engl J Med., 2001, 345(12): 851-860.
S., Abiko, A., Naganuma, Y., Moriai, Y., Nakamura, M. Effects of telmisartan on
adiponectin levels and body weight in hypertensive patients with glucose
intolerance. Metabolism, 2008, 10:
H., Okada, Y., Arao, T., Nishida, K., Tanaka, Y. Telmisartan at 80mg/day
increases high-molecular-weight adiponectin levels and improves insulin
resistance in diabetic patients. Adv Ther,
2012, 29(7): 635-44.
R., Formoso, G., Hassan, H. The effects of irbesartan and telmisartan on
metabolic parameters and blood pressure in obese, insulin resistant,
hypertensive patients. J Endocrinol
Invest., 2006, 29(11): 957-61.
Investigators, Yusuf, S., Teo, K.K., et al. Telmisartan, ramipril, or both in
patients at high risk for vascular events. N
Engl J Med., 2008, 358:1547–1559.
R., Ging, Y., Berzins, B., Wu, X., Mahadev, K., Hough, K., Chan, L., Goldstein,
B.J., Scalia, R. Adiponectin deficiency increases leucocytes endothelium
interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest., 2007, 117: 1718-1726.
K.G., Munzel, F., Krekler, M. Effect of the angiotensin receptor blocker
irbesartan on metabolic parameters in clinical practice: the DO-IT prospective
observational study. Cardiovascular Diabetology,
2007, 6: 36-41.
H-H., Lennert, H., Brochner-mortensen, J., Gomis, R., Andersen, S., Avner, P. The
effect of irbesartan on the development of diabetic nephropathy in patients
with type-2 diabetes. N Engl J Med.,
2001, 345(12): 870-78.
Investigators (Trials of Hypertension Prevention Collaborative Research Group).Effects
of weight loss and sodium reduction intervention on blood pressure and
hypertension incidence in overweight people with high-normal blood pressure.
The Trials of Hypertension Prevention, phase II. Arch Intern Med., 1997, 157:657-67.
[20.] World Health
Report (2002) Reducing risks, promoting healthy life. World Health
Organization, Geneva, Switzerland. http://www.who.int/whr/2002/en/whr02_en.Pdf